Definition: A combined index providing a measure of disease activity, comprising:

1. the number of swollen joints (of a possible 28);
2. the number of tender joints (of a possible 28); and
3. either erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) level (DAS28-ESR and DAS28-CRP, respectively).

Definition: A composite index for assessing disease activity based on:

1. swollen joint count (of a possible 28);
2. tender joint count (of a possible 28);
3. patient’s global assessment of disease activity (VAS); and
4. physician’s global assessment of disease activity (VAS).

Definition: The numerical sum of five measures:

1. swollen joint count (of a possible 28);
2. tender joint count (of a possible 28);
3. patient’s global assessment of disease activity (VAS);
4. physician’s global assessment of disease activity (VAS); and
5. levels of CRP.

American College of Rheumatology response criteria

1. patient global VAS;
2. patient pain VAS;
3. physician global VAS;
4. HAQ score;
5. acute-phase reactant value (ESR or CRP).

Link to further information: https://www.rheumatology.org/Portals/0/Files/ACR_Core_Disease_Activity_RA_Clinical_Trials93.pdf

European League Against Rheumatism response criteria

Moderate response: More than a 1.2-point improvement in DAS28, with a present score of more than 3.2 points, or an improvement in DAS28 of >0.6 to ≤1.2 points, with a present score of 5.1 points or lower.
No response: Improvement in DAS28 of >0.6 to ≤1.2 points, with a present score of more than 5.1 points, or an improvement in DAS28 of 0.6 points or less, regardless of present score.

Modified total Sharp/van der Heijde score

Link to further information: https://ard.bmj.com/content/62/7/597

Links to further information: https://www.rheumatic.theclinics.com/article/S0889-857X(09)00077-5/fulltext
https://www.rheumatology.org/Portals/0/Files/RAPID3%20Form.pdf

Definition: An extension of the WOMAC score developed with the purpose of evaluating long- and short-term symptoms and function in people with osteoarthritis and knee injury. The KOOS includes five self-reported subscales:

1. pain;
2. other symptoms;
3. function in daily living;
4. function in sport and recreation;
5. knee-related quality of life.

Kellgren and Lawrence system for classification of osteoarthritis

Definition: A method based on radiographic measures for classifying the severity of knee osteoarthritis using five grades, from 0 (indicating no presence of osteoarthritis) to 4 (indicating severe osteoarthritis).

Measure of Intermittent and Constant Osteoarthritis Pain

Definition: An 11-item measure for the assessment of pain in people with knee or hip osteoarthritis, taking into account intermittent and constant pain experiences.

Response criteria from the Outcome Measures in Rheumatology and Osteoarthritis Research Society International committees

Definition: A set of treatment response criteria based on pain and function. Response defined as:

• 50% or greater improvement in pain or function and an absolute change of at least 20 points; or
• 20% or greater improvement and absolute change of at least 10 points in at least two out of pain, function, and patient's global assessment.

Definition: A measure of disease activity in patients with ankylosing spondylitis, including patient-reported levels of:

1. back pain;
2. fatigue;
3. peripheral joint pain and swelling;
4. localized tenderness; and
5. duration and severity of morning stiffness.

Links to further information: http://basdai.com/
https://onlinelibrary.wiley.com/doi/full/10.1002/acr.20575

Assessment of SpondyloArthritis international Society response criteria 

Definition: At least a 20%, 40%, 50%, or 70% improvement and an absolute improvement of at least 1 unit on a scale of 1–10 in at least three of the following criteria:

1. patient global assessment;
2. pain;
3. function (BASFI); and
4. inflammation (duration and severity of morning stiffness as measured by BASDAI).

Definition: A five-domain composite score taking into account joint disease, skin involvement, enthesitis, dactylitis and spinal disease. Each domain is graded from 0 to 3 points, giving a CPDAI range of 0–15.

Definition: A composite index originally developed for reactive arthritis, based on tender and swollen joint counts, patient pain assessment, patient global assessment, and CRP.

Definition: A composite score taking into account assessments of joints, skin, function, pain, and health-related quality of life. The GRACE score ranges from 0 (worst) to 10 (best) points.

Definition: A weighted index comprising assessments of joints, function, quality of life, acute-phase response, and patient and physician assessments.

American College of Rheumatology response criteria

1. patient global VAS;
2. patient pain VAS;
3. physician global VAS;
4. HAQ score;
5. acute-phase reactant value (ESR or CRP).

Link to further information: https://www.rheumatology.org/Portals/0/Files/ACR_Core_Disease_Activity_RA_Clinical_Trials93.pdf

Modified total Sharp/van der Heijde score

Link to further information: https://ard.bmj.com/content/62/7/597

Psoriasis Area and Severity Index response criteria

Links to further information: https://www.pasitraining.com/
https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.12817

Definition: A "satisfactory state" of disease activity defined according to the MDA criteria. MDA is defined as meeting five of the following seven criteria:

1. tender joint count ⩽1;
2. swollen joint count ⩽1;
3. PASI ⩽1 or body surface area ⩽3;
4. patient pain VAS ⩽15;
5. patient global disease activity VAS ⩽20;
6. HAQ ⩽0.5; and
7. tender entheseal points ⩽1.

Links to further information: https://www.clinexprheumatol.org/article.asp?a=8761 
https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.1780350606

Links to further information: https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-015-0702-6
https://www.clinexprheumatol.org/article.asp?a=8761

Definition: A composite index to measure disease activity, defined as:

1. at least a 4-point reduction in the SELENA-SLEDAI score;
2. no new BILAG A or no more than one new BILAG B domain score; and
3. no more than a 0.3-point worsening in Physician’s Global Assessment.

Links to further information: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2748175/
https://academic.oup.com/rheumatology/article/55/8/1357/2566467

Definition: A measure of low disease activity based on the following criteria:

1. SLEDAI-2K of 4 points or less, with no activity in major organ systems and no hemolytic anemia or gastrointestinal activity;
2. no new lupus disease activity since the previous assessment;
3. SELENA-SLEDAI physician’s global assessment of disease activity score of 1 point or lower on a scale of 0–3 points;
4. current prednisolone or equivalent dose of 7.5 mg/day or lower; and
5. well-tolerated maintenance doses of immunosuppressive agents and approved biologics.

Link to further information: https://ard.bmj.com/content/75/9/1615

Juvenile idiopathic arthritis response criteria

Definition: At least a 30%, 50%, 70%, or 90% improvement from baseline in any three of the following six variables in juvenile idiopathic arthritis (JIA) patients, with no more than one variable worsening by more than 30%:

1. physician’s global assessment of disease activity;
2. parent/guardian’s or patient’s global assessment of overall wellbeing;
3. functional ability;
4. number of joints with active arthritis;
5. number of joints with limited range of motion; and
6. ESR.

Definition: A composite disease activity score for JIA including four measures:

1. physician’s global assessment of disease activity;
2. parent/guardian’s or patient’s global assessment of overall wellbeing;
3. number of joints with active arthritis; and
4. ESR.

The JADAS-71 includes a complete joint count (71 joints) in addition to the other measures, while the JADAS-27 and JADAS-10 include reduced joint counts (27 and 10 joints, respectively).

Links to further information: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.24516
https://ard.bmj.com/content/72/12/1983

Definition: A clinical three-item version of the JADAS score that excludes ESR or CRP. The cJADAS includes the following variables that are measured routinely in clinical settings:

1. physician global assessment of disease activity;
2. parent/guardian or patient global assessment of overall wellbeing; and
3. number of joints with active arthritis.

Link to further information: https://doi.org/10.1136/annrheumdis-2012-202031

Criteria for inactive disease developed by Carol Wallace and colleagues.

1. no active arthritis;
2. no fever, rash, serositis, splenomegaly, or generalized lymphadenopathy attributable to JIA;
3. no active uveitis;
4. normal ESR or CRP; and
5. physician's global assessment of disease activity rated at the best score possible for the instrument used.